Search

everythinglearnresearchcommunity

for

Search:↓

Future hair loss treatments should aim to extend hair growth, reactivate resting follicles, reverse shrinkage, and possibly create new follicles, with gene therapy showing promise.

The article suggests using four questions to tell apart necessary medicalization from excessive medicalization, focusing on problem significance, social expectations, medical understanding, and effective resolution.

Dutasteride safely promotes hair growth and reduces hair loss, with mild side effects.

Finasteride has a higher risk of reproductive side effects than minoxidil.

Negative expectations can cause adverse effects in dermatology treatments, like with finasteride for baldness, and careful communication can help reduce these nocebo responses.

Finasteride can cause sexual dysfunction and depression, which may persist and require hormonal treatment.

Menopause often leads to lower sexual desire and discomfort during sex, but treatment should be personalized and only if it bothers the woman.

Environmental factors and exposure to toxins may contribute to male infertility by affecting sperm and hormone function.

Hair loss can be treated with medications like minoxidil and finasteride or surgery, but treatment effectiveness varies by alopecia type and accurate diagnosis is important.

Dutasteride helps hair growth in those unresponsive to finasteride, but may cause more sexual dysfunction.

Higher DHT levels are linked to fewer hypogonadism symptoms in men with normal testosterone levels.

5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.

The treatment effectively promoted hair growth with minimal side effects.

Treatments for enlarged prostate can cause problems with ejaculation, and less invasive options might preserve sexual function better.

Female pattern hair loss does not significantly affect sexual dysfunction.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.

The document concludes that diagnosing and treating hair loss is complex and requires understanding its psychological effects and underlying causes, while also calling for more research and new treatments.

Post-finasteride syndrome causes sexual, physical, and psychological symptoms, but more research is needed to understand its causes and connection to finasteride.

The article concludes that different types of hair loss require specific treatments and psychological support is important.

Dihydrotestosterone gel before hypospadias surgery led to less scarring but raised concerns about potential psychological effects and skin changes.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

Male pattern hair loss caused by follicular miniaturization; early diagnosis and treatment can reduce psychological burden.

Testosterone significantly affects sexual desire in both men and women, but its impact on women is more complex and influenced by psychological factors.

The document concludes that accurate diagnosis and appropriate management are crucial for treating various hair disorders, which have significant psychological impacts.

The true incidence of post-Finasteride syndrome is unclear, and more research is needed.

Finasteride can cause long-lasting sexual dysfunction even after stopping the drug.

Premature hair graying is caused by genetics, stress, and lifestyle, and affects mental health.

New biomaterial treatments for baldness show promise, with options depending on patient needs.

Gendered social factors, not just biology, contribute to sex differences in adverse drug events.